Source: www.clinicaltrials.gov
US-based, Cala Health, has recently introduced Cala Trio Therapy as the first non-invasive targeted therapy which reduces hand tremors for people living Essential Tremor (ET). According to a study by American Academy of Neurology, ET is most common in people aged 40 years or older and affects nearly 6.4 million people in the US.
This ground-breaking therapy, cala trio, is caliberated to treat tremor which is a common motor symptom of parkinson’s, that was earlier irreversibly debilitating. It is a wearable worn on the wrist which measures specific tremor and sends a gentle stimulation to the radial and medial nerves that travels to the brain. Thus interrupting the tremor in the ventral intermediate nucleus of the thalamus.
The USP of the device is that it is a personalized therapy for essential tremor and is the only non-invasive prescription therapy for ET. The device targets the same site in the brain where tremor is well-controlled by deep brain stimulation (DBS)- thalamus. Cala health recently received FDA breakthrough device designation for expansion into hand tremors associated with parkinson’s disease. Cala health was also a nominee for Prix Galien’s best medical technology award in 2021.
